Comparative evaluation of the efficacy and safety of intra-articular administration of hyaluronic acid and glucocorticoids in the complex therapy of osteoarthritis

Improving the treatment of knee (KN) osteoarthritis (OA) remains an urgent problem.
Objective: to compare the efficacy and tolerability of intra-articular (i/a) administration of long-acting glucocorticoids (GCs) and Armaviscon®Forte and Armaviscon®Platinum hyaluronates in patients with knee OA.
Material and methods. From November 2019 to April 2022, we examined and treated 60 patients (26 men and 34 women, mean age 41.32±3.71 years) suffering from primary KN OA. Study participants were randomly divided into three groups of 20 patients each. In the 1st group, a longacting GCs in combination with a local anesthetic was administered once i/a into the KN, in the 2nd – Armaviscon®Forte 2.3%, and in the 3rd – Armaviscon®Platinum 3%.
Patients were examined at baseline, on the 14th and 60th day after a single injection of the drug. The intensity of pain was assessed on a visual analog scale (VAS), the Lequesne index, the KOOS, WOMAC, and EQ-5D questionnaires were used. When studying tolerability, the number of adverse reactions (ARs) was taken into account.
Results. By the end of the observation period in the study groups, there was a decrease in the severity of pain and an increase in functionality with positive dynamics of the Lequesne and WOMAC indices. Both hyaluronic acid drugs had a positive effect on the functional state of the joints according to KOOS, improved the quality of life according to EQ-5D. The need for non-steroidal anti-inflammatory drugs in patients of the 2^nd and 3rd groups decreased down to their complete cancellation. No adverse events requiring discontinuation of therapy have been reported. The advantage of i/a administration of hyaluronates in comparison with long-acting GCs was shown.
Conclusion. In real clinical practice, in patients with symptomatic OA, i/a administration of hyaluronates allows obtaining more favorable results than the use of long-acting HA.

1. Alekseeva LI. Osteoarthrosis. In: Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR Media; 2020. 448 p.

2. Naimann AI. Current trends in the treatment of osteoarthritis. Intra-articular use of hyaluronic acid derivatives. Lechashchii vrach. 2018;(7):42-5. (In Russ.).

3. Peshekhonova LK, Peshekhonov DV. The main trends in pathogenetic therapy of osteoartrosis. Russkii meditsinskii zhurnal. 2012;(30):1500-4. (In Russ.).

4. Nasonov EL, Chichasova NV, Kovalev VYu. Local therapy with glucocorticoids. Russkii meditsinskii zhurnal. 1999;(8):7-10. (In Russ.).

5. Nasonov EL. General characteristics and mechanisms of action of the GC. Russkii meditsinskii zhurnal. 1999;(8):4-7. (In Russ.).

6. Fallacara A, Baldini E, Manfredini S,Vertuani S. Hyaluronic Acid in the Third Millennium. Polymers (Basel). 2018 Jun 25; 10(7):701. doi: 10.3390/polym10070701.

7. Udovika MN, Zhilyaev EV, Anoshenkova ON. The effectiveness of local injections of sodium hyaluronate in the treatment of diseases of soft periarticular tissues. Poliklinika. 2017;(2): 98-104. (In Russ.).

8. Peshekhonova LK, Peshekhonov DV, Krasyukov PA. Topical issues of osteoarthritis therapy in real clinical practice. Meditsinskii sovet. 2017;(1S):97-102. (In Russ.).

9. Altman R, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16:321. doi: 10.1186/s12891-015-0775-z.

10. George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis. 1998 Nov;57(11):637-40. doi: 10.1136/ard.57.11.637.

11. Bowman S, Awad ME, Hamrick MW, et al. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018 Feb 16;7(1):6. doi: 10.1186/s40169-017-0180-3.

12. Navarro-Sarabia F, Coronel P, Collantes E, et al. A 40-month multicentre, randomized placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011 Nov;70(11):1957-62. doi: 10.1136/ard.2011.152017. Epub 2011 Aug 17.

13. Hermans J, Bierma-Zeinstra SMA, Bos PK, et al. The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial. BMC Musculoskelet Disord. 2019 May 7;20(1):196. doi: 10.1186/s12891-019-2546-8.

14. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008.

15. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991 May;34(5):505-14. doi: 10.1002/art.1780340502.

16. Fisher Yu. Lokal'noe lechenie boli [Local pain treatment]. Moscow: MEDpress-inform; 2019. P. 176.

17. Akhmerov RR, editor. Regenerativnaya meditsina na osnove autologichnoi plazmy. Tekhnologiya Plasmolifting TM [Regenerative medicine based on autologous plasma. Plasmolifting TM technology]. Moscow: Litterra; 2014. 150 p.

18. Malanin DA, Demkin SA, Demeshchenko MV, Baidova KV. Platelet-rich autologous plasma in the treatment of patients with stage II osteoarthritis of the knee joint. Genii ortopedii. 2017;23(1):44-51. (In Russ.).